Tolerability and Efficacy of RJX in Patients With COVID-19
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study is designed as a 2-part, 2-cohort, double-blind, randomized, placebo controlled,
multicenter Phase 1/2 study to evaluate the safety, tolerability and efficacy of RJX in
patients with COVID-19.